Pharmaceutical giant Roche announced that it will invest US$50 billion into the U.S. in the next five years. The expansion of Switzerland-based Roche’s U.S. footprint will involve new and expanded manufacturing and distribution facilities nationwide.
Roche plans to expand and upgrade facilities in Kentucky, Indiana, New Jersey, Oregon and California; build a gene therapy manufacturing facility in Pennsylvania; build a manufacturing facility for continuous glucose monitoring in Indiana; add an R&D center in Massachusetts; and construct a 900,000-square-foot manufacturing center for next-generation weight loss medicines, at a location to be announced.
“Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world,” said Thomas Schinecker, Roche Group CEO.
Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the U.S. than it imports.
Pictured: Roche’s Genentech campus in San Francisco.
The post Roche Plans $50B Expansion of U.S. Manufacturing Footprint appeared first on Connect CRE.